Chronic Spontaneous Urticaria Market 2024 - By Size, Share, Trends Analysis Report And Forecasts To 2033

Overview and Scope

Chronic spontaneous urticaria (CSU) is a skin condition characterized by the recurrent appearance of hives (raised, red, itchy welts) and angioedema (swelling) lasting for more than six weeks, without an identifiable external trigger. The exact cause of CSU is often unknown, but it may involve an autoimmune component where the body's immune system mistakenly attacks healthy skin cells. Treatment focuses on symptom management, primarily using antihistamines and, in more severe cases, other medications such as biologics.

Sizing and Forecast

The chronic spontaneous urticaria market size has grown strongly in recent years. It will grow from $1.90 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%.  The growth in the historic period can be attributed to improved diagnostic tools, growing awareness among healthcare, patient advocacy and support groups, ongoing studies and clinical trials exploring new therapies, and growing healthcare expenditure.

The chronic spontaneous urticaria market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%.  The growth in the forecast period can be attributed to an increase in the number of diagnosed CSU cases, a growing patient pool, healthcare infrastructure development, favorable regulatory environment facilitating, patient-centric care models, and economic growth in emerging markets. Major trends in the forecast period include technology innovations, biological therapy advancements, personalized medicine, telemedicine and digital health, advanced diagnostic tools, AI and machine learning, and surging drug approvals and launches.

Order your report now for swift delivery, visit the link:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Segmentation & Regional Insights

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Major Driver Impacting Market Growth

Increasing alcohol consumption is expected to propel the growth of the chronic spontaneous urticaria market going forward. The rising consumption of alcohol can be attributed to various factors, such as social norms, stress, advertising, affordability, and availability. Alcohol consumption can potentially exacerbate symptoms of chronic spontaneous urticaria in some individuals, leading to increased hives and swelling. For instance, in February 2024, according to rehabs.UK, a UK-based provider of addiction recovery support and advice services, 55% of men reported weekly alcohol consumption, while 41% of women. Additionally, 8% of men reported drinking alcohol almost daily, compared to 5% of women. Over the years from 2021 to 2022, there were 342,795 hospital admissions solely attributable to alcohol, translating to a rate of 626 admissions per 100,000 people. Therefore, increasing alcohol consumption is driving the growth of the chronic spontaneous urticaria market.

Key Industry Players

Major companies operating in the chronic spontaneous urticaria market are  F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

The chronic spontaneous urticaria market report table of contents includes:

1. Executive Summary

2. Chronic Spontaneous Urticaria Market Characteristics

3. Chronic Spontaneous Urticaria Market Trends And Strategies

4. Chronic Spontaneous Urticaria Market - Macro Economic Scenario

5. Global Chronic Spontaneous Urticaria Market Size and Growth

............................

32. Global Chronic Spontaneous Urticaria Market Competitive Benchmarking

33. Global Chronic Spontaneous Urticaria Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chronic Spontaneous Urticaria Market

35. Chronic Spontaneous Urticaria Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info 

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model